Company news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM) news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B news releases on 6ix. Latest, Apr 26, 2021: Concerned Shareholders Issue Information Circular for FSD…
View Quantum Biopharma Ltd. Subordinate Voting Shares Class B →
Press releases — page 5
Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy
April 25, 2021
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting
April 5, 2021
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued Shares
March 8, 2021
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
September 28, 2020
FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19
August 31, 2020
FSD Pharma Reports Second Quarter 2020 Financial Results
August 7, 2020
FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors
August 6, 2020
FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video
July 31, 2020
FSD Pharma Inc. Announces US$10 Million Registered Direct Offering
July 31, 2020
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.
July 30, 2020
FSD Pharma Announces US$20M At-The-Market Offering
July 13, 2020
InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com
June 23, 2020
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
June 9, 2020
FSD Pharma Inc. Announces C$10.125 Million Private Placement
June 4, 2020
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
June 3, 2020
FSD Pharma Reports First Quarter 2020 Financial Results
May 14, 2020
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario
March 23, 2020
InvestmentPitch Media Video Discusses FSD Pharma's Initiation of Phase 1 In-Human Safety & Tolerability Study of Dosing Ultra Micro-PEA for Targeting CB2 Receptors at Alfred Hospital in Australia - Video Available on Investmentpitch.com
March 10, 2020
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
March 9, 2020
FSD Pharma Inc., Worldwide License of Natural Fatty Acid, CEO Clip Video
March 6, 2020
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020
March 4, 2020
InvestmentPitch Media Video Discusses FSD Pharma's Sale of its 12% Interest in Cannara Biotech Generating 670% Return and $7.7 million in Proceeds - Video Available on Investmentpitch.com
February 24, 2020
FSD Pharma CEO, Dr. Raza Bokhari, Discusses 2020 Goals with The Stock Day Podcast
February 11, 2020
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
February 5, 2020
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
February 4, 2020
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
January 17, 2020
InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com
January 10, 2020
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'
January 9, 2020
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020
January 6, 2020
FSD Pharma Strengthens Management Team
January 2, 2020
FSD Pharma Receives Approval to List its Shares on Nasdaq
December 16, 2019
FSD Pharma to Present at Investor Summit on December 17
December 13, 2019
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11
December 5, 2019
FSD Pharma Reports Third Quarter 2019 Financial Results
November 29, 2019
FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering
November 4, 2019
FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018
October 23, 2019
FSD Pharma Announces Temporary Change in OTCQB Ticker Symbol to FSDDD
October 17, 2019
FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation
October 11, 2019
FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering
October 1, 2019
InvestmentPitch Media Video Discusses FSD Pharma's LOI with World Class Extractions Creating JV to Build and Operate Cannabis Extraction/Processing Facility in Cobourg, Ontario - Video Available on Investmentpitch.com
September 26, 2019
FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center
September 25, 2019
FSD Pharma Joins The Stock Day Podcast to Discuss Their Expanding Revenue Potential
September 12, 2019
FSD Pharma Announces Private Placement
August 30, 2019
FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment
August 21, 2019
FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals
July 2, 2019
FSD Pharma Receives Full "Sale for Medical Purposes" Cannabis License from Health Canada
June 24, 2019
FSD Pharma Continues to Add Expert Advisors Amid Buildout of Massive Facility -- CFN Media
June 14, 2019
FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors
June 12, 2019
FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board
June 6, 2019
FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division -- CFN Media
June 4, 2019